

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §1.97(b)(4)

Applicant hereby submits a Supplemental Information Disclosure Statement (IDS) under 37 C.F.R. §1.97(b)(4) before the mailing of a first Office Action on the merits after a request for continued examination in the above referenced application. This IDS further supplements the IDS submitted on 15 October 2003 and 22 February 2008.

In accordance with 37 C.F.R. §1.97(g) and (h), this submission shall not be construed as representation that a search has been made or as admission that information presented or cited herein is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

In accordance with 37 C.F.R. §1.98, Applicant submits herewith (1) a listing on Form PTO-1449 of documents requested to be considered by the Examiner and (2) a legible copy of each listed document, except for U.S. patents and U.S. patent application publications.

Consideration by the Examiner of the present submission is requested

Respectfully submitted,
HARNESS, DICKEY & PIERCE, P.L.C.



Leanne M. Rakers
Attorney for Applicant
Reg. No. 64,412
Harness, Dickey & Pierce, P.L.C.
7700 Bonhomme, Suite 400
St. Louis, Missouri 63105
314.726.7514 (direct)
314.726.7501 (fax)

Attachment
Form PTO-1449
cited document
60537422.1

FORM HDP-1449 (Based on Form PTO-1449)

PATENT AND TRADEMARK OFFICE
INFORMATION DISCLOSURE CITATION
 (Use several sheets if necessary)

Sheet 1 of 1

ATTORNEY DOCKET NO.	SERIAL NO.
6102-000069/US	10/623,864
APPLICANT	
Schacht, D.W. <i>et al.</i>	
FILING DATE	GROUP
July 22, 2003	1611

U.S. PATENT DOCUMENTS

Ref. Desig.	Examiner's Initials	Document Number	Publication Date	Name	Class/ Subclass	Filing Date
		2004/0034083	Feb 19, 2004	Stephenson <i>et al.</i>	514/406	Apr 14, 2003
		2004/0209861	Oct 21, 2004	Benavides, <i>et al.</i>	514/210.01	Feb 25, 2004

OTHER DOCUMENTS

Ref. Desig.	Examiner's Initials	
		Van der Weide, <i>et al.</i> (1988) "The enantiomers of the D-2 dopamine receptor agonist N-0437 discriminate between pre- and postsynaptic dopamine receptors." Eur J Pharmacol 146:319-326

60584781.1

Examiner:

Date Considered:

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.